Cargando…

Candesartan Cilexetil Attenuates Arrhythmogenicity Following Pressure Overload in Rats via the Modulation of Cardiac Electrical and Structural Remodeling and Calcium Handling Dysfunction

BACKGROUND: Cardiac hypertrophy is associated with abnormal electrophysiology and increased arrhythmia risk. This study assessed whether candesartan cilexetil, an angiotensin II type 1 receptor blocker, could suppress arrhythmogenecity by attenuating cardiac electrical remodeling and calcium mishand...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Gwo‐Jyh, Yeh, Yung‐Hsin, Chen, Wei‐Jan, Ko, Yu‐Shien, Lai, Ying‐Ju, Lee, Yun‐Shien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375482/ https://www.ncbi.nlm.nih.gov/pubmed/35862154 http://dx.doi.org/10.1161/JAHA.121.024285

Ejemplares similares

Candesartan cilexetil in the treatment of chronic heart failure
por: Baguet, Jean-Philippe, et al.
Publicado: (2009)

Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study
por: Baguet, JP, et al.
Publicado: (2009)

Candesartan cilexetil: COVID-19 pneumonia: case report
Publicado: (2020)

Repurposing Candesartan Cilexetil as Antibacterial Agent for MRSA Infection
por: Xu, Lanlan, et al.
Publicado: (2021)

Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T)
por: Bönner, Gerd, et al.
Publicado: (2011)

Design and development and evaluation of candesartan cilexetil liquid filling formulations
por: Deepthi, Y., et al.
Publicado: (2015)

Development of Orodispersible Tablets of Candesartan Cilexetil-β-cyclodextrin Complex
por: Sravya, Maddukuri, et al.
Publicado: (2013)

The Effect of Polysorbate 20 on Solubility and Stability of Candesartan Cilexetil in Dissolution Media
por: Hoppe, Katarzyna, et al.
Publicado: (2014)

Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug
por: Aly, Usama Farghaly, et al.
Publicado: (2020)

Formulation and Bioavailability of Novel Mucoadhesive Buccal Films for Candesartan Cilexetil in Rats
por: Mady, Omar Y., et al.
Publicado: (2021)

Chemometric Methods for Simultaneous Determination of Candesartan Cilexetil and Hydrochlorothiazide in Binary Combinations
por: Ali, Diyar Salahuddin
Publicado: (2023)

Enhanced Antihypertensive Activity of Candesartan Cilexetil Nanosuspension: Formulation, Characterization and Pharmacodynamic Study
por: Detroja, Chetan, et al.
Publicado: (2011)

Candesartan Cilexetil In Vitro–In Vivo Correlation: Predictive Dissolution as a Development Tool
por: Figueroa-Campos, Andrés, et al.
Publicado: (2020)

New simple spectrophotometric method for determination of the binary mixtures (atorvastatin calcium and ezetimibe; candesartan cilexetil and hydrochlorothiazide) in tablets
por: Belal, Tarek S., et al.
Publicado: (2013)

Development and characterization of controlled release polar lipid microparticles of candesartan cilexetil by solid dispersion
por: Kamalakkannan, V, et al.
Publicado: (2013)

Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility
por: Mengden, Thomas, et al.
Publicado: (2009)

Bioequivalence study of two formulations of candesartan cilexetil tablet in healthy subjects under fasting conditions
por: Tjandrawinata, Raymond R, et al.
Publicado: (2013)

Nephroprotective effects of Candesartan Cilexetil against Cyclosporine A-induced nephrotoxicity in a rat model
por: Ghafil, Fadhaa Abdulameer, et al.
Publicado: (2022)

The Anti-inflammatory Compound Candesartan Cilexetil Improves Neurological Outcomes in a Mouse Model of Neonatal Hypoxia
por: Quinlan, Sean, et al.
Publicado: (2019)

New Peceol™/Span™ 60 Niosomes Coated with Chitosan for Candesartan Cilexetil: Perspective Increase in Absolute Bioavailability in Rats
por: AbuElfadl, Aya, et al.
Publicado: (2021)

Developing pH-Modulated Spray Dried Amorphous Solid Dispersion of Candesartan Cilexetil with Enhanced In Vitro and In Vivo Performance
por: Poudel, Surendra, et al.
Publicado: (2021)

Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: meta-analysis of five randomized double-blind clinical trials
por: Féghali, Ramzi EL, et al.
Publicado: (2007)

A validated ultra high-pressure liquid chromatography method for separation of candesartan cilexetil impurities and its degradents in drug product
por: Kumar, Namala Durga Atchuta, et al.
Publicado: (2012)

Enhancing the Oral Bioavailability of Candesartan Cilexetil Loaded Nanostructured Lipid Carriers: In Vitro Characterization and Absorption in Rats after Oral Administration
por: Anwar, Walid, et al.
Publicado: (2020)

Candesartan cilexetil prevents diet-induced insulin resistance via peroxisome proliferator-activated receptor-γ activation in an obese rat model
por: YAN, WEN-HUA, et al.
Publicado: (2016)

Pharmacokinetics and bioequivalence of fixed-dose combination of candesartan cilexetil/amlodipine besylate (16/10 mg) versus coadministration of individual formulations in healthy subjects
por: Lee, Hae Won, et al.
Publicado: (2020)

Effects of Candesartan on Electrical Remodeling in the Hearts of Inherited Dilated Cardiomyopathy Model Mice
por: Odagiri, Fuminori, et al.
Publicado: (2014)

Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical study
por: Rakugi, Hiromi, et al.
Publicado: (2012)

A Novel DES L115F Mutation Identified by Whole Exome Sequencing is Associated with Inherited Cardiac Conduction Disease
por: Hsu, Lung-An, et al.
Publicado: (2019)

Candesartan, an angiotensin-II receptor blocker, ameliorates insulin resistance and hepatosteatosis by reducing intracellular calcium overload and lipid accumulation
por: Lee, Jin Wook, et al.
Publicado: (2023)

Candesartan Cilexetil Improves Angiotensin II Type 2 Receptor–Mediated Neurite Outgrowth via the PI3K-Akt Pathway in Fructose-Induced Insulin-Resistant Rats
por: Hashikawa-Hobara, Narumi, et al.
Publicado: (2012)

Profibrotic, Electrical, and Calcium-Handling Remodeling of the Atria in Heart Failure Patients With and Without Atrial Fibrillation
por: Molina, Cristina E., et al.
Publicado: (2018)

Proinflammatory Cytokine Modulates Intracellular Calcium Handling and Enhances Ventricular Arrhythmia Susceptibility
por: Tsai, Yung-Nan, et al.
Publicado: (2021)

Modeling the Effects of Calcium Overload on Mitochondrial Ultrastructural Remodeling
por: Strubbe-Rivera, Jasiel O., et al.
Publicado: (2021)

CD44 regulates Epac1-mediated β-adrenergic-receptor-induced Ca(2+)-handling abnormalities: implication in cardiac arrhythmias
por: Chan, Yi-Hsin, et al.
Publicado: (2023)

Mutagenic Assessment of Olmesartan Cilexetil by Bacterial Mutation Assay
por: Kim, Ji Won, et al.
Publicado: (2013)

Arrhythmogenic Remodeling in the Failing Heart
por: Husti, Zoltán, et al.
Publicado: (2021)

Sodium overload due to a persistent current that attenuates the arrhythmogenic potential of a novel LQT3 mutation
por: Moreau, Adrien, et al.
Publicado: (2013)

Effects of Dantrolene on Arrhythmogenicity in Isolated Regional Ischemia-Reperfusion Rabbit Hearts with or without Pacing-Induced Heart Failure
por: Chou, Chung-Chuan, et al.
Publicado: (2015)

Alterations in Calcium Handling Are a Common Feature in an Arrhythmogenic Cardiomyopathy Cell Model Triggered by Desmosome Genes Loss
por: Vallverdú-Prats, Marta, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q808auj5clcabie7gs2ku16bnp